Institute for Medical Genetics and Applied Genomics (IMGAG)
AG: Genetic Variants of Proximal Signaling
Peer-reviewed Journal Publications
2026
Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies.
Valentin P. Shichkin, Ahsen Morva, Vijay K. Ulaganathan, Nuray Erin, Cristina Nativi, Simona Kranjc Brezar & Sweta Rani.
Molecular Cancer. 20262024
CD24 flags anastasis in melanoma cells.
Vasileva MH, Bennemann A, Zachmann K, Schön MP, *Frank J, *Ulaganathan VK.
Apoptosis. 20242023
A strategy for uncovering germline variants altering anti-tumour CD8 T cell response.
Vasileva M, *Ulaganathan VK.
J Genet Genomics. 20232022
Membrane Anchorage-Induced (MAGIC) Knockdown of Non-synonymous Point Mutations.
*Ulaganathan VK.
ChemBioChem. June 3, 20222020
TraPS-VarI: TraPS-VarI: Identifying genetic variants altering phosphotyrosine based signalling motifs.
*Ulaganathan VK
Scientific Reports. 10, 8453. 2020 Supplementary Data2018
STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion.
Kogan D, Grabner A, Yanucil C, Faul C, *Ulaganathan VK.
Journal of Clinical Investigation. Feb 13, 2018 Supplemental Information2016
Membrane-proximal binding of STAT3 revealed by cancer-associated receptor variants.
*Ulaganathan VK, *Ullrich A.
Molecular & Cellular Oncology. 20162015
Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site.
*Ulaganathan VK, Sperl B, Rapp UR, *Ullrich A.
Nature. Dec 24, 20152014
Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells.
Kopp F, Hermawan A, Oak PS, Ulaganathan VK, Herrmann A, Elnikhely N, Thakur C,Xiao Z, Knyazev P, Ataseven B, Savai R, Wagner E, Roidl A.
Translational Oncology. Dec, 20142013
Neo-epitope tissue transglutaminase autoantibodies as a biomarker of the gluten sensitive skin disease--dermatitis herpetiformis.
Lytton SD, Antiga E, Pfeiffer S, Matthias T, Szaflarska-Poplawska A, Ulaganathan VK, Placek W, Fabbri P, Hall R, Caproni M.
Clin Chim Acta. Jan 16, 20132012
T cells become licensed in the lung to enter the central nervous system.
Odoardi F, Sie C, Streyl K, Ulaganathan VK, Schläger C, Lodygin D, Heckelsmiller K, Nietfeld W, Ellwart J, Klinkert WE, Lottaz C, Nosov M, Brinkmann V, Spang R, Lehrach H, Vingron M, Wekerle H, Flügel-Koch C, Flügel A.
Nature. Aug 30, 20122010
Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the CNS.
Cordiglieri C, Odoardi F, Zhang B, Nebel M, Kawakami N, Klinkert WE, Lodygin D, Lühder F, Breunig E, Schild D, Ulaganathan VK, Dornmair K, Dammermann W, Potter BV, Guse AH, Flügel.
Brain. 2010Other Publications
- Ulaganathan VK. Defying Paradigms: A Curiosity-Driven Exploration of pTyr-SNVs in Cancer (March 17, 2025) The EACR Cancer Researcher - Online magazine [https://magazine.eacr.org/defying-paradigms-a-curiosity-driven-exploration-of-ptyr-snvs-in-cancer/].
- Ulaganathan VK. CD24: A Cell Surface Marker for Anastasis in Melanoma (April 19, 2024) [https://communities.springernature.com/posts/cd24-a-cell-surface-marker-for-anastasis-in-melanoma].
- *Ulaganathan VK, Ullrich A. DNA-dependent protein synthesis exhibited by cancer shed particulates. bioRxiv. March 27, 2017: 121186 [doi: 10.1101/121186].
- *Ulaganathan VK. An FGFR4 Germline Variant Activates STAT3 Signaling. Cancer Discovery February 1 2016 (6) (2) OF8 [doi: 10.1158/2159-8290.CD-RW2015-241].
- *Ulaganathan VK, B. Sperl, T. Mayr, R. Hornberger, U.R. Rapp, A. Ullrich. A gain of function by the cancer-associated FGFR4 c.1162G>A (p.Gly388Arg) variant. European Journal of Cancer. (2014) Volume 50 , S107 – S108. [doi: 10.1016/S0959-8049(14)50398-X]
- Ulaganathan VK. Tumor-extrinsic Immune Evasion in the Tumor Microenvironment (May 17, 2018) Technology Networks: Exploring the Science that Matters to You [https://www.technologynetworks.com/tn/articles/tumor-extrinsic-immune-evasion-in-the-tumor-microenvironment-302929].
- Gene variation promotes uncontrolled cell division (Dec 16, 2015). Max-Planck-Gesselschaft Newsroom [https://www.mpg.de/9805116/gene-cancer-heritage].
Invention Disclosures
- 2017 Invention disclosure MPG15748EP Max Planck Innovation GmbH.
- 2017 Invention disclosure MPG15750EP Max Planck Innovation GmbH.
Invited Talks and Presentations in Refereed Conference Proceedings
2024
- Ulaganathan VK, “Dual Impact Phosphotyrosine SNVs – Potential Genetic Modifiers of Anti-Tumor Immune Response”, Deutsche Gesellschaft für Immunologie DGfI. October 08, 2024 [Invited Speaker].
2020
- Ulaganathan VK, “Harnessing Membrane-proximal Tyrosine Phosphorylation for Precision”, KU Leuven, Department of Human Genetics 16 Jan, 2020 [Invited Speaker].
2019
- Ulaganathan VK, “Signaling Biology in the post-genome Era”, Universitäts Salzburg, Department of Biological Sciences 08 July, 2019 [Invited Speaker].
2017
- Ulaganathan VK, “Harnessing Membrane-proximal Tyrosine Phosphorylation for Precision Medicine”, Ludwig-Maximilians-Universität München, Pathology Institute 10 October, 2017 [Invited Speaker].
- Ulaganathan VK, “Breaking the wall of undruggability”, Falling Walls Lab 2017, Jülich 18 September, 2017 [Invited Speaker].
- Ulaganathan VK, “Harnessing the spatially regulated tyrosine phosphorylation mechanisms for precision medicine”, EACR-AACR-SIC Special Conference 2017, Florence, Italy 25 June, 2017 [Invited Speaker].
- Ulaganathan VK, “Harnessing the spatially regulated molecular mechanisms for precision medicine in cancer”, International conference on "Sharing radically novel visions in Cancer" – a Think-tank Meeting 2017, Berlin 03 June, 2017 [Invited Speaker].
2016
- Ulaganathan VK, “A germline receptor variant modulating STAT3 signalling”, Max Planck Institute of Biochemistry (MPIB) 2016 Junior Research Award Lecture, Martinsried 24 July, 2016 [Invited Speaker].
2014
- Ulaganathan VK, “Human Germline Variations in Cancer Progression”, Winter Lecture Series: International Max Planck Research School (IMPRS-LS) Lecture, Martinsried 30 October, 2014 [Invited Speaker].